Internship

Intern – Clinical Biometrics

PhD

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Paid internship at South San Francisco headquarters for approximately 10-12 weeks.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
R
Data Analysis
Requirements
  • PhD candidate of either Statistics or Biostatistics and accomplished core courses for the program
  • A strong understanding of clinical trial data and experience in statistical analysis
  • Proficiency in programming languages such as R and/or SAS, particularly for data analysis and simulations
  • Strong presentation skills with the ability to effectively communicate research findings to diverse audiences
Responsibilities
  • conducting statistical simulations using Markov chain Monte Carlo and other statistical methods to evaluate potential impacts of study outcomes under different hypothetical scenarios
  • develop a solid understanding of statistical methods from practical perspectives
  • gain proficiency in a range of simulation and statistical methods with various analysis strategies
  • build experience in presenting the findings

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma to advance its cardiovascular R&D pipeline.
  • Positive Phase III trial results for aficamten show promise in treating hypertrophic cardiomyopathy.
  • Increased focus on personalized medicine aligns with Cytokinetics' individualized dosing strategies.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos may impact aficamten's market share.
  • Reliance on successful clinical trials poses risks if outcomes are negative.
  • Substantial funding needs indicate financial pressure and dependency on external capital.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets niche markets like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics employs personalized medicine strategies, enhancing individualized dosing for better patient outcomes.

Help us improve and share your feedback! Did you find this helpful?